Corleen M. Roche - 09 Mar 2026 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Reporting relationship: Chief Financial Officer
Issuer ticker: IOVA
Reported as of: 09 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Mar 2026, 17:25:27 UTC
Prior SEC filing: 08 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Corleen Roche

Key filing fact

Corleen M. Roche filed Form 4 for IOVANCE BIOTHERAPEUTICS, INC. (IOVA) on 11 Mar 2026.

Key facts

This page summarizes Corleen M. Roche's Form 4 filing for IOVANCE BIOTHERAPEUTICS, INC. (IOVA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Mar 2026, 17:25.

Change

Previous filing in this sequence was filed on 08 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001857905 Primary reporting owner

Roche Corleen M.

Relationship: Chief Financial Officer
Address: C/O IOVANCE BIOTHERAPEUTICS, INC., 825 INDUSTRIAL ROAD, SUITE 100, SAN CARLOS
Signature: /s/ Corleen Roche
Signature date: 11 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IOVA transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +132,200
Change %
Price: $0.000000^*
Shares after: 132,200
Date: 09 Mar 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 132,200
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

Footnote F2

Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.